Summary: Rhenium-188 SSS/Lipiodol, a therapeutic analogue of 188Re-HDD/Lipiodol, is an innovative radiopharmaceutical under development for treating hepatocellular carcinoma (HCC) complicated by portal vein thrombosis (PVT). This mixture combines iodinated fatty acid ethyl esters derived from poppy seed oil (Lipiodol™) with a radioactive rhenium complex soluble in oil. Its mechanism targets fatty acid-containing tissues, utilising Lipiodol as a carrier. Delivering beta radiation (β–), the molecule aims to provide targeted radioembolisation therapy for non-resectable and untransplantable HCC cases. Following the completion of Phase I trials in 2022, this novel approach could potentially enhance treatment outcomes in a challenging clinical landscape.
Keywords: 188Re-SSS/Lipiodol; Hepatocellular carcinoma; Portal vein thrombosis; Radioembolization; Radiopharmaceuticals; Beta radiation therapy.
Introduction to Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadly cancers worldwide, particularly in regions with high rates of hepatitis B and C infections. Complications such as portal vein thrombosis (PVT) significantly worsen the prognosis, limiting treatment options. For non-resectable and untransplantable cases, radioembolisation has emerged as a promising therapy. Among the radiopharmaceuticals being developed, Rhenium-188 SSS/Lipiodol offers a novel approach, building on the clinical success of its analogue, 188Re-HDD/Lipiodol. This article explores the structure, mechanism, and therapeutic potential of 188Re-SSS/Lipiodol, highlighting its significance in addressing unmet medical needs in HCC treatment.
Structure and Composition of Rhenium-188 SSS/Lipiodol
188Re-SSS/Lipiodol is a complex formulation comprising:
- Lipiodol™: A radiopaque oil composed of ethyl esters of iodinated fatty acids from poppy seed oil, serving as the carrier.
- Radioactive Rhenium Complex: Rhenium-188, a beta-emitting radionuclide, is chemically bound to a ligand that is soluble in Lipiodol.
This composition ensures targeted delivery of beta radiation to fatty acid-rich tissues, such as liver tumours, while minimising systemic exposure. The lipophilic nature of Lipiodol allows prolonged retention in hepatic tissues, enhancing therapeutic efficacy.
Mechanism of Action
The mechanism of Rhenium-188 SSS/Lipiodol leverages the affinity of Lipiodol for fatty acid-containing tissues, particularly in the liver. Key aspects of its action include:
- Selective Uptake: Lipiodol preferentially accumulates in HCC lesions due to their aberrant vascularisation and lipid metabolism.
- Beta Radiation Delivery: Rhenium-188 emits beta particles (β–) that induce cytotoxic damage to cancer cells.
- Localised Effect: The oil-based carrier limits dispersion, ensuring radiation remains focused on the tumour and surrounding microenvironment.
This targeted mechanism is particularly advantageous for treating HCC with PVT, where systemic chemotherapy or surgery is not feasible.
Clinical Development and Phase I Trial
The clinical evaluation of Rhenium-188 SSS/Lipiodol began with a Phase I trial completed in 2022. The trial focused on safety, dosage optimisation, and preliminary efficacy.
- Design: The study enrolled patients with advanced, non-resectable HCC and PVT, administering escalating doses of Rhenium-188 SSS/Lipiodol via transarterial injection.
- Outcomes: The trial demonstrated a favourable safety profile, with manageable toxicity and encouraging signs of tumour control.
- Implications: These findings paved the way for further studies to establish optimal therapeutic regimens and validate efficacy in larger populations.
Advantages Over Existing Therapies
Rhenium-188 SSS/Lipiodol presents several advantages compared to conventional treatments for HCC with PVT:
- Minimally Invasive: Administered through transarterial radioembolisation, avoiding major surgical interventions.
- Targeted Action: Reduces off-target effects and systemic toxicity, improving patient tolerability.
- Dual Functionality: Combines radiotherapy and embolisation, disrupting tumour blood supply while delivering cytotoxic radiation.
- Scalability: Utilises Rhenium-188, a generator-produced radionuclide, ensuring cost-effectiveness and widespread availability.
Challenges and Future Directions
Despite its promise, the development and implementation of 188Re-SSS/Lipiodol face several challenges:
- Dosimetry Optimisation: Determining precise radiation doses to maximise efficacy while minimising toxicity.
- Patient Selection: Identifying subgroups most likely to benefit from the therapy.
- Regulatory Approval: Ensuring compliance with stringent regulatory standards for radiopharmaceuticals.
Future research should focus on:
- Phase II and III trials to establish efficacy and long-term outcomes.
- Comparative studies with alternative treatments like 90Y-microspheres or systemic therapies.
- Investigating combination strategies with immunotherapies or targeted agents to enhance treatment synergy.
Conclusion
Rhenium-188 SSS/Lipiodol represents a significant advancement in the treatment of hepatocellular carcinoma with portal vein thrombosis. By harnessing the unique properties of Lipiodol and the therapeutic potential of Rhenium-188, this innovative radiopharmaceutical offers hope for patients with limited options. As it progresses through clinical development, 188Re-SSS/Lipiodol has the potential to redefine the standard of care for a challenging subset of HCC cases, ultimately improving survival and quality of life.
You are here: home »